The clinical course of idiopathic pulmonary fibrosis and its association to quality of life over time: longitudinal data from the INSIGHTS-IPF registry.


Journal

Respiratory research
ISSN: 1465-993X
Titre abrégé: Respir Res
Pays: England
ID NLM: 101090633

Informations de publication

Date de publication:
15 Mar 2019
Historique:
received: 11 12 2018
accepted: 27 02 2019
entrez: 17 3 2019
pubmed: 17 3 2019
medline: 6 8 2019
Statut: epublish

Résumé

Quality of life (QoL) is profoundly impaired in patients with idiopathic pulmonary fibrosis (IPF). However, data is limited regarding the course of QoL. We therefore analysed longitudinal data from the German INSIGHTS-IPF registry. Clinical status and QoL were assessed at enrollment and subsequently at 6- to 12-months intervals. A range of different QoL questionnaires including the St. George's Respiratory Questionnaire (SGRQ) were used. Data from 424 patients were included; 76.9% male; mean age 68.7 ± 9.1 years, mean FVC% predicted 75.9 ± 19.4, mean DL QoL assessments in the INSIGHTS-IPF registry demonstrate a close relationship between QoL and clinically meaningful changes in lung function, comorbidities, disease duration and clinical course of IPF, including hospitalisation and mortality.

Sections du résumé

BACKGROUND BACKGROUND
Quality of life (QoL) is profoundly impaired in patients with idiopathic pulmonary fibrosis (IPF). However, data is limited regarding the course of QoL. We therefore analysed longitudinal data from the German INSIGHTS-IPF registry.
METHODS METHODS
Clinical status and QoL were assessed at enrollment and subsequently at 6- to 12-months intervals. A range of different QoL questionnaires including the St. George's Respiratory Questionnaire (SGRQ) were used.
RESULTS RESULTS
Data from 424 patients were included; 76.9% male; mean age 68.7 ± 9.1 years, mean FVC% predicted 75.9 ± 19.4, mean DL
CONCLUSIONS CONCLUSIONS
QoL assessments in the INSIGHTS-IPF registry demonstrate a close relationship between QoL and clinically meaningful changes in lung function, comorbidities, disease duration and clinical course of IPF, including hospitalisation and mortality.

Identifiants

pubmed: 30876420
doi: 10.1186/s12931-019-1020-3
pii: 10.1186/s12931-019-1020-3
pmc: PMC6420774
doi:

Types de publication

Journal Article Multicenter Study

Langues

eng

Pagination

59

Références

N Engl J Med. 2010 Aug 12;363(7):620-8
pubmed: 20484178
Thorax. 2010 Oct;65(10):921-6
pubmed: 20861296
Am J Respir Crit Care Med. 2011 Mar 15;183(6):788-824
pubmed: 21471066
Respir Med. 2012 Oct;106(10):1447-55
pubmed: 22801586
Dtsch Med Wochenschr. 2012 Dec;137(49):2586-8
pubmed: 23188642
Thorax. 2013 Sep;68(9):867-79
pubmed: 23204065
N Engl J Med. 2014 May 29;370(22):2071-82
pubmed: 24836310
N Engl J Med. 2014 May 29;370(22):2083-92
pubmed: 24836312
Health Qual Life Outcomes. 2014 Aug 20;12:124
pubmed: 25138056
BMJ Open Respir Res. 2014 Jan 03;1(1):e000010
pubmed: 25478169
BMJ Open Respir Res. 2014 May 13;1(1):e000024
pubmed: 25478176
Eur Respir J. 2015 Jul;46(1):186-96
pubmed: 25837040
Eur Respir J. 2015 Oct;46(4):1113-30
pubmed: 26424523
Lung. 2016 Apr;194(2):227-34
pubmed: 26861885
Respir Med. 2016 Apr;113:74-9
pubmed: 26915984
PLoS One. 2016 Mar 29;11(3):e0151425
pubmed: 27023440
Respiration. 2016;91(6):497-502
pubmed: 27240427
Respir Res. 2017 Jan 17;18(1):18
pubmed: 28095852
Eur Respir J. 2017 Jan 18;49(1):
pubmed: 28100551
Respirology. 2017 Jul;22(5):950-956
pubmed: 28166611
Respir Res. 2017 Jul 14;18(1):139
pubmed: 28709421
BMC Pulm Med. 2017 Jul 25;17(1):104
pubmed: 28743305
BMC Pulm Med. 2017 Oct 10;17(1):130
pubmed: 29017478
Lancet Respir Med. 2017 Dec;5(12):968-980
pubmed: 29033267
Front Med (Lausanne). 2017 Dec 20;4:226
pubmed: 29326935
J Cardiopulm Rehabil Prev. 2018 Sep;38(5):273-278
pubmed: 29351129
BMC Pulm Med. 2018 Jan 25;18(1):19
pubmed: 29370786
Respir Res. 2018 May 25;19(1):101
pubmed: 29801506
BMJ Open Respir Res. 2018 May 18;5(1):e000278
pubmed: 29862029
N Engl J Med. 2018 Nov 1;379(18):1722-1731
pubmed: 30220235

Auteurs

Michael Kreuter (M)

Center for interstitial and rare lung diseases, Thoraxklinik, University of Heidelberg, Röntgenstr 1, D-69126, Heidelberg, Germany. kreuter@uni-heidelberg.de.
German Center for Lung Research, gießen, Germany. kreuter@uni-heidelberg.de.

Jeff Swigris (J)

Interstitial Lung Disease Program, National Jewish Health, Denver, CO, USA.

David Pittrow (D)

Institut für Klinische Pharmakologie, Medizinische Fakultät, Technische Universität Dresden, Dresden, Germany.

Silke Geier (S)

Department Market Access, Boehringer Ingelheim, Ingelheim am Rhein, Germany.

Jens Klotsche (J)

Epidemiologie, Deutsches Rheuma-Forschungsinstitut, Berlin, Germany.

Antje Prasse (A)

Klinik für Pneumologie, Medizinische Hochschule Hannover, Hannover, Germany.
Fraunhofer Institute ITEM, Hannover, Germany.
German Center for Lung Research, gießen, Germany.

Hubert Wirtz (H)

Abteilung für Pneumologie, Department Innere Medizin, Neurologie und Dermatologie, Universitätsklinikum Leipzig AöR, Leipzig, Germany.

Dirk Koschel (D)

Zentrum für Pneumologie und Bereich Pneumologie, Fachkrankenhaus Coswig und Uniklinikum Dresden, Coswig, Germany.

Stefan Andreas (S)

Lungenfachklinik Immenhausen and Universitätsmedizin Göttingen, Kardiologie und Pneumologie, Göttingen, Germany.

Martin Claussen (M)

Lungen Clinic Grosshansdorf, Grosshansdorf, Germany.
German Center for Lung Research, gießen, Germany.

Christian Grohé (C)

Klinik für Pneumologie - ELK, Berlin Buch, Berlin, Germany.

Henrike Wilkens (H)

Klinik für Innere Medizin V, Pneumologie, Universitätsklinikum Universitätskliniken des Saarlandes, Homburg, Germany.

Lars Hagmeyer (L)

Krankenhaus Bethanien, Solingen, Germany.

Dirk Skowasch (D)

Medizinische Klinik und Poliklinik II, Universitätsklinikum Bonn, Bonn, Germany.

Joachim F Meyer (JF)

Lungenzentrum München, LZM Bogenhausen-Harlaching, Städtisches Klinikum München GmbH, Munich, Germany.

Joachim Kirschner (J)

Center for Internal Medical Studies CIMS, Bamberg, Germany.

Sven Gläser (S)

Klinik und Poliklinik für Innere Medizin B, Forschungsbereich Pneumologie und Pneumologische Epidemiologie, Universitätsmedizin Greifswald, Greifswald, Germany.
Vivantes Klinikum Spandau, Klinik für Innere Medizin, Berlin, Germany.

Nicolas Kahn (N)

Center for interstitial and rare lung diseases, Thoraxklinik, University of Heidelberg, Röntgenstr 1, D-69126, Heidelberg, Germany.
German Center for Lung Research, gießen, Germany.

Tobias Welte (T)

Klinik für Pneumologie, Medizinische Hochschule Hannover, Hannover, Germany.
German Center for Lung Research, gießen, Germany.

Claus Neurohr (C)

Medizinische Klinik und Poliklinik V, Klinikum der LMU, Munich, Germany.
Schillerhöhe, Robert Bosch Krankenhaus, Stuttgart, Germany.

Martin Schwaiblmair (M)

Medizinische Klinik, Klinikum Augsburg, Augsburg, Germany.

Matthias Held (M)

Klinikum Würzburg Mitte, Standort Missioklinik, Abteilung Innere Medizin, Pneumologie, Würzburg, Germany.

Thomas Bahmer (T)

Lungen Clinic Grosshansdorf, Grosshansdorf, Germany.
German Center for Lung Research, gießen, Germany.

Tim Oqueka (T)

Universitätsklinikum Hamburg, Hamburg, Germany.

Marion Frankenberger (M)

Medizinische Klinik und Poliklinik V, Klinikum der LMU, Munich, Germany.
Asklepios Fachkliniken München-Gauting, Munich, Germany.
German Center for Lung Research, gießen, Germany.

Jürgen Behr (J)

Medizinische Klinik und Poliklinik V, Klinikum der LMU, Munich, Germany.
Asklepios Fachkliniken München-Gauting, Munich, Germany.
German Center for Lung Research, gießen, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH